Total Payments
$1.2M
2024 Payments
$88,499
Companies
57
Transactions
1,456
Medicare Patients
2,125
Medicare Billing
$169,986
Payment Breakdown by Category
Other$615,053 (50.2%)
Consulting$408,687 (33.4%)
Research$89,350 (7.3%)
Travel$86,048 (7.0%)
Food & Beverage$25,771 (2.1%)
Education$394.67 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $461,093 | 248 | 37.6% |
| Consulting Fee | $408,687 | 144 | 33.4% |
| Honoraria | $153,085 | 68 | 12.5% |
| Unspecified | $89,350 | 63 | 7.3% |
| Travel and Lodging | $86,048 | 290 | 7.0% |
| Food and Beverage | $25,771 | 606 | 2.1% |
| Grant | $875.00 | 2 | 0.1% |
| Education | $394.67 | 35 | 0.0% |
Payments by Type
General
$1.1M
1,393 transactions
Research
$89,350
63 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shire North American Group Inc | $190,277 | 217 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $146,276 | 176 | $0 (2024) |
| CSL Behring | $107,613 | 158 | $0 (2024) |
| Pharming Healthcare, Inc. | $105,543 | 127 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $102,268 | 105 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $78,449 | 48 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $70,492 | 101 | $0 (2024) |
| F. Hoffmann-La Roche AG | $67,418 | 41 | $0 (2024) |
| GENZYME CORPORATION | $60,087 | 42 | $0 (2024) |
| Merck Sharp & Dohme LLC | $52,527 | 47 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $88,499 | 127 | F. Hoffmann-La Roche AG ($17,263) |
| 2023 | $80,614 | 124 | Novartis Pharmaceuticals Corporation ($16,572) |
| 2022 | $89,606 | 101 | Novartis Pharmaceuticals Corporation ($14,632) |
| 2021 | $165,931 | 179 | Takeda Pharmaceuticals U.S.A., Inc. ($30,480) |
| 2020 | $137,330 | 123 | Takeda Pharmaceuticals U.S.A., Inc. ($25,896) |
| 2019 | $215,413 | 251 | Shire North American Group Inc ($54,566) |
| 2018 | $244,054 | 295 | Shire North American Group Inc ($68,580) |
| 2017 | $203,856 | 256 | Shire North American Group Inc ($67,130) |
All Payment Transactions
1,456 individual payment records from CMS Open Payments — Page 1 of 59
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,796.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/19/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $354.80 | General |
| 12/17/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,645.10 | General |
| 12/17/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $629.30 | General |
| 12/17/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $514.90 | General |
| 12/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $31.46 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $5,050.00 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $774.99 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $262.20 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $218.41 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $171.46 | General |
| 12/10/2024 | Incyte Corporation | OPZELURA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $317.50 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $5.58 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/02/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Consulting Fee | Cash or cash equivalent | $5,850.00 | General |
| Category: BIOLOGIC | ||||||
| 12/02/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Travel and Lodging | In-kind items and services | $525.00 | General |
| Category: BIOLOGIC | ||||||
| 12/02/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $212.59 | General |
| Category: BIOLOGIC | ||||||
| 11/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Consulting Fee | Cash or cash equivalent | $2,860.00 | General |
| Category: GENETIC DISEASE | ||||||
| 11/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Travel and Lodging | In-kind items and services | $529.86 | General |
| Category: GENETIC DISEASE | ||||||
| 11/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Travel and Lodging | In-kind items and services | $36.36 | General |
| Category: GENETIC DISEASE | ||||||
| 11/25/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| Category: BIOLOGIC | ||||||
| 11/20/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $132.56 | General |
| Category: BIOLOGIC | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $129.03 | General |
| 11/19/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $6.22 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $15,603 | 14 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $8,050 | 1 |
| Characteristics of Patients with Chronic Spontaneous Urticaria Who are Late-Responders to Omalizumab | F. Hoffmann-La Roche AG | $6,034 | 1 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $5,867 | 1 |
| Real-World Outcomes in Patients with Chronic Spontaneous Urticaria Receiving Omalizumab: Insights from a Clinical Practice Survey | F. Hoffmann-La Roche AG | $5,310 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma | SANOFI-AVENTIS U.S. LLC | $5,281 | 11 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH XOLAIR RESEARCH | Novartis Pharmaceuticals Corporation | $5,250 | 1 |
| OUTCOMES RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $5,232 | 1 |
| Impact of Baseline Angioedema and IgE on Response to Omalizumab in Chronic Spontaneous Urticaria | F. Hoffmann-La Roche AG | $3,861 | 2 |
| A CENTER-BASED CHART REVIEW DESCRIBING THE DIAGNOSIS AND TREATMENT RESPONSE OF PATIENTS WITH HEREDITARY ANGIOEDEMA WITH NORMAL C1-INHIBITOR (NC1-INH HAE) | Takeda Pharmaceuticals U.S.A., Inc. | $3,564 | 1 |
| Time To Clinically Meaningful Response To Omalizumab In Patients With Chronic Spontaneous Urticaria | F. Hoffmann-La Roche AG | $3,193 | 2 |
| Does Angioedema in Patients with Chronic Spontaneous Urticaria Impact the Response to Omalizumab? | F. Hoffmann-La Roche AG | $3,150 | 1 |
| Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status | F. Hoffmann-La Roche AG | $2,625 | 1 |
| Patients With Chronic Spontaneous Urticaria May Benefit From Longer Treatment Or Updosing With Omalizumab | F. Hoffmann-La Roche AG | $2,554 | 2 |
| A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids | GENZYME CORPORATION | $2,250 | 6 |
| Real-World Survey Outcomes For Chronic Spontaneous Urticaria For Patients On Omalizumab Versus Patients Eligible For Omalizumab | F. Hoffmann-La Roche AG | $2,232 | 1 |
| OUTCOMES RESEARCH | Novartis Pharmaceuticals Corporation | $1,308 | 1 |
| A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids | GENZYME CORPORATION | $1,250 | 1 |
| Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab | GENZYME CORPORATION | $1,250 | 1 |
| An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | CSL Behring | $1,079 | 5 |
| Characteristics Of Patients With Chronic Spontaneous Urticaria Who Are Early Responders To Omalizumab | F. Hoffmann-La Roche AG | $1,055 | 1 |
| Omalizumab Efficacy in Patients with Chronic Spontaneous Urticaria and Comorbid Asthma | F. Hoffmann-La Roche AG | $1,055 | 1 |
| An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma | SANOFI-AVENTIS U.S. LLC | $983.08 | 2 |
| Improving The Quality Of Care For Patients With CSU: Study Design And Patient Baseline Characteristics | F. Hoffmann-La Roche AG | $659.38 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma | GENZYME CORPORATION | $334.67 | 1 |
| ASP2b | SANOFI-AVENTIS U.S. LLC | $320.69 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 419 | 639 | $102,415 | $38,252 |
| 2022 | 7 | 473 | 800 | $102,190 | $38,011 |
| 2021 | 12 | 621 | 1,452 | $135,925 | $50,194 |
| 2020 | 12 | 612 | 1,398 | $136,725 | $43,529 |
Total Patients
2,125
Total Services
4,289
Medicare Billing
$169,986
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 195 | 323 | $58,140 | $26,019 | 44.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 37 | 37 | $12,025 | $4,257 | 35.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 52 | 60 | $8,400 | $3,155 | 37.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $6,020 | $2,235 | 37.1% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 67 | 70 | $9,100 | $1,210 | 13.3% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 17 | 97 | $3,880 | $711.93 | 18.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 18 | 18 | $4,050 | $433.17 | 10.7% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2023 | 19 | 20 | $800.00 | $231.37 | 28.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 164 | 247 | $44,460 | $20,595 | 46.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 136 | 177 | $24,780 | $9,707 | 39.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 48 | 48 | $15,600 | $5,211 | 33.4% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 77 | 81 | $10,530 | $1,355 | 12.9% |
| 95117 | Professional service for multiple injections of allergen | Office | 2022 | 15 | 73 | $2,920 | $452.15 | 15.5% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 13 | 153 | $3,060 | $412.08 | 13.5% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2022 | 20 | 21 | $840.00 | $279.86 | 33.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 154 | 237 | $42,660 | $21,041 | 49.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 196 | 283 | $39,620 | $16,154 | 40.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 49 | 49 | $15,925 | $5,779 | 36.3% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 82 | 84 | $10,920 | $1,667 | 15.3% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2021 | 32 | 387 | $7,740 | $1,214 | 15.7% |
| 95018 | Allergy testing with drugs or biologicals into or within the skin, immediate type reaction, including test interpretation and report | Office | 2021 | 13 | 72 | $3,240 | $1,166 | 36.0% |
| 95117 | Injection of incremental dosages of allergen, 2 or more injections | Office | 2021 | 15 | 115 | $4,600 | $788.58 | 17.1% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 12 | 12 | $2,640 | $726.15 | 27.5% |
| 95024 | Injection of allergenic extracts into skin for immediate reaction analysis | Office | 2021 | 18 | 84 | $2,100 | $541.67 | 25.8% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2021 | 12 | 12 | $2,700 | $420.48 | 15.6% |
About Dr. Jonathan Bernstein, MD
Dr. Jonathan Bernstein, MD is a Internal Medicine healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1093713638.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Bernstein, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $88,499 received in 2024. These payments were reported across 1,456 transactions from 57 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($461,093).
As a Medicare-enrolled provider, Bernstein has provided services to 2,125 Medicare beneficiaries, totaling 4,289 services with total Medicare billing of $169,986. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Allergy & Immunology
- Location Cincinnati, OH
- Active Since 07/08/2005
- Last Updated 07/14/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1093713638
Products in Payments
- CINRYZE (Drug) $149,684
- RUCONEST (Biological) $103,543
- DUPIXENT (Biological) $100,378
- FASENRA (Drug) $77,231
- Haegarda (Biological) $75,795
- Xolair (Biological) $74,211
- TAKHZYRO (Biological) $48,583
- DUPIXENT DUPILUMAB INJECTION (Biological) $40,606
- NUCALA (Biological) $37,167
- Xhance (Drug) $29,475
- SPIRIVA (Drug) $24,332
- XOLAIR (Biological) $22,508
- DUPIXENT (Drug) $22,029
- Orladeyo (Drug) $19,241
- FASENRA (Biological) $16,085
- SPIRIVA RESPIMAT (Drug) $14,398
- CUVITRU (Biological) $14,195
- HYQVIA (Biological) $8,989
- ORLADEYO (Drug) $8,727
- VTAMA (Drug) $7,320
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Cincinnati
Nelson Watts, M.d, M.D
Internal Medicine — Payments: $788,194
Internal Medicine $788,194
Robert Baughman, M.d, M.D
Internal Medicine — Payments: $766,919
Internal Medicine $766,919
Mark Andolina, Md, MD
Internal Medicine — Payments: $469,821
Internal Medicine $469,821
Amit Govil, M.d, M.D
Internal Medicine — Payments: $410,360
Internal Medicine $410,360
Vincent Martin, Md, MD
Internal Medicine — Payments: $332,673
Internal Medicine $332,673
Jean Elwing, Md, MD
Internal Medicine — Payments: $266,596
Internal Medicine $266,596